Attached is a letter to the editor of the Kidney Cancer Journal and editorial response regarding the use of checkpoint inhibitors in non-clear cell RCC. We’re grateful to the editors of the journal for graciously providing this update for patients with rare types of kidney cancer.
Letter to Kidney Cancer Journal and Response – Regarding Checkpoint Inhibitors in Non-Clear Cell RCC
